{"disease":{"id":"advanced-malignancies","name":"advanced malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03084471","title":"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":867,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05417594","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":695,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06468098","title":"A Study of IBI363 in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":556,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT04389541","title":"Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02383212","title":"Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07022002","title":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT04916119","title":"Study of IBI323 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":322,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07136779","title":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT07448922","title":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":290,"lead_sponsor_name":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","has_results":false},{"nct_id":"NCT02737501","title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":true},{"nct_id":"NCT04085185","title":"A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05315167","title":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":267,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT06717880","title":"A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07299747","title":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":255,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT05735275","title":"A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02608268","title":"Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":252,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01058707","title":"Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03474640","title":"Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"TopAlliance Biosciences","has_results":true},{"nct_id":"NCT04752826","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT06937957","title":"A Study of BR111 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":166,"lead_sponsor_name":"BioRay Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02381886","title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05028478","title":"A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT04181788","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03082209","title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT03233139","title":"Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03126110","title":"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":true},{"nct_id":"NCT02000934","title":"A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT03363893","title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Carrick Therapeutics Limited","has_results":false},{"nct_id":"NCT06206915","title":"Phase I Study of XZ120 in Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT05023486","title":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":121,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07426757","title":"An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03780517","title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT00830869","title":"A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06224855","title":"A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou DAC Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT01899053","title":"A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07155811","title":"Lymphocyte Function Testing in Immuno-oncology","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06649708","title":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","has_results":false},{"nct_id":"NCT02697591","title":"A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":true},{"nct_id":"NCT02118337","title":"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT00979134","title":"Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04328831","title":"Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT03386526","title":"APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT00500903","title":"A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02923349","title":"A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":true},{"nct_id":"NCT02265510","title":"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Incyte Corporation","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}